Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Fineline Cube Dec 5, 2025
Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025
Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025
Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025
Company Deals

Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough

Fineline Cube Dec 4, 2025
Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025
Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Fineline Cube Dec 5, 2025
Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025
Company Drug

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention

Fineline Cube Sep 3, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that China’s National Medical Products...

Company Drug

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults

Fineline Cube Sep 3, 2025

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) today announced that the United States...

Policy / Regulatory

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs

Fineline Cube Sep 3, 2025

The National Medical Products Administration (NMPA) today announced the release of its 95th Reference‑Listed Drugs...

Company Drug

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors

Fineline Cube Sep 3, 2025

China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) today announced that its novel...

Company Drug

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide

Fineline Cube Sep 3, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) disclosed encouraging topline results from the...

Company Deals Drug

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule

Fineline Cube Sep 3, 2025

OMass Therapeutics, a biotechnology firm that discovers medicines targeting membrane proteins and intracellular complexes, has...

Company Deals

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy

Fineline Cube Sep 3, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today unveiled a worldwide licensing and collaboration agreement with Novartis...

Company Deals

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma

Fineline Cube Sep 2, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced a landmark exclusive licensing collaboration with RADIANCE Biopharma....

Company Drug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Fineline Cube Sep 2, 2025

China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has secured a pivotal regulatory milestone:...

Company Drug

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer

Fineline Cube Sep 2, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced the nationwide launch of...

Company Drug

Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations

Fineline Cube Sep 2, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that the Biologics License...

Company Drug

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977

Fineline Cube Sep 2, 2025

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the U.S. Food and Drug Administration...

Company Drug

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China

Fineline Cube Sep 2, 2025

Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost/timolol maleate) in...

Company Deals

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies

Fineline Cube Sep 2, 2025

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149) and Hayoo Biotech have...

Company Drug

Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS

Fineline Cube Sep 2, 2025

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Ltd...

Company Drug

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease

Fineline Cube Sep 2, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its inebilizumab injection has received...

Others

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP

Fineline Cube Sep 1, 2025

The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi’s (NASDAQ: SNY) Wayrilz...

Company Deals

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia

Fineline Cube Sep 1, 2025

Eli Lilly (NYSE: LLY) China has announced a strategic partnership with JD Health (HKG: 6618)...

Company Drug

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone

Fineline Cube Sep 1, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its oral primary biliary cholangitis (PBC) treatment,...

Company Drug

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402

Fineline Cube Sep 1, 2025

Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...

Posts pagination

1 … 36 37 38 … 594

Recent updates

  • Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform
  • Juventas CAR-T LBCL Launch Marks Second Indication
  • BMS Breyanzi MZL FDA Approval First CAR-T
  • Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient
  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.